GlassScriptPhysician profile
Erin K Espinoza
NPI 1285020875
$3,538.88
in general payments reported to CMS, 2019-2025
41 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $274 · 2022: $208 · 2023: $790 · 2024: $948 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,936.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $432.90 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $418.11 | 2023-2025 | |
| Celgene Corporation | $352.12 | 2019-2024 | Reblozyl, Pomalyst |
| Alexion Pharmaceuticals, INC. | $201.19 | 2022-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $194.97 | 2023-2025 | Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $189.57 | 2023-2025 | Vanflyta, Enhertu, Injectafer |
| Pfizer INC. | $159.31 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $156.20 | 2020-2023 | Imbruvica, Epkinly |
| Seagen INC. | $152.61 | 2020-2023 | Padcev, Tukysa |
| Abbvie INC. | $105.32 | 2024-2025 | |
| Genentech USA, INC. | $91.38 | 2022-2024 | Polivy, Lunsumio, Columvi |
| Emd Serono, INC. | $88.42 | 2023-2025 | Tepmetko |
| Merck Sharp & Dohme LLC | $84.02 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $69.60 | 2020-2025 | Rybrevant, Talvey, Tecvayli |
| Regeneron Healthcare Solutions, INC. | $68.52 | 2022-2025 | Libtayo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $68.34 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Amgen INC. | $54.93 | 2022 | |
| Lilly USA, LLC | $52.65 | 2023 | Retevmo, Verzenio, Jaypirca |
| Agios Pharmaceuticals, INC. | $51.19 | 2024-2025 | Pyrukynd |
| Genmab U.S., INC. | $48.98 | 2023-2025 | Epkinly |
| Glaxosmithkline, LLC. | $44.07 | 2025 | Blenrep, Ojjaara |
| Incyte Corporation | $42.87 | 2024 | Jakafi, Monjuvi, Pemazyre |
| Cumberland Pharmaceuticals, INC. | $34.18 | 2023-2025 | Sancuso |
| Kite Pharma, INC. | $30.96 | 2024 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $30.14 | 2023-2024 | Opdivo |
| Deciphera Pharmaceuticals INC. | $27.29 | 2023 | Qinlock |
| Bayer Healthcare Pharmaceuticals INC. | $23.80 | 2023 | |
| Apellis Pharmaceuticals, INC. | $22.24 | 2025 | Empaveli |
| Pharmaessentia USA Corporation | $21.90 | 2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $21.71 | 2024 | |
| Octapharma USA, INC. | $21.45 | 2024 | Octagam Immune Globulin (Human) |
| Tersera Therapeutics LLC | $20.96 | 2024 | Zoladex |
| Recordati_rare_diseases_inc. | $20.58 | 2025 | Sylvant |
| Gilead Sciences, INC. | $20.47 | 2025 | Trodelvy |
| Sumitomo Pharma America, INC. | $19.37 | 2023 | Orgovyx |
| Sun Pharmaceutical Industries INC. | $18.59 | 2024 | |
| Novo Nordisk INC | $17.00 | 2023 | Rebinyn, Novoeight |
| Syndax Pharmaceuticals, INC. | $16.79 | 2025 | |
| Secura Bio, INC. | $15.54 | 2024 | Copiktra |
| Cti Biopharma Corp. | $15.34 | 2023 | Vonjo |
| Sobi, INC | $13.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Espinoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.